The move hastens the demise of the malaria drug as a potential treatment for the disease.
News & Analysis: Novartis
It's a face-off between an incredibly cheap stock and a pharmaceutical giant.
Each company has a triad of COVID-19 projects, but they aren't in direct competition.
FDA Revokes Emergency Use Authorization for Hydroxychloroquine and Chloroquine as COVID-19 Treatments
The agency found no evidence to support the theory that the antimalarial drugs touted by President Trump are effective against the coronavirus.
NVS earnings call for the period ending March 31, 2020.
The healthcare regulator says that hydroxychloroquine and chloroquine are causing dangerous heart issues in coronavirus patients.
These three stocks aren't just surviving the coronavirus storm -- they're thriving in it.
Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.
The death rate among COVID-19 patients who were given the malaria drug was more than twice as high as among those who weren't.
The FDA has approved the pharma giant's plan for a large phase 3 study of the malaria treatment against COVID-19.